Trial Profile
Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 23 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 19 Jul 2011 Planned end date changed from Jun 2010 to Sep 2012 as reported by ClinicalTrials.gov.
- 28 Jan 2010 New trial record